Vaccination against SARS-CoV-2 in Guinea-Bissau
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25761/anaisihmt.428 |
Resumo: | Vaccination is defined as one of the safest ways to protect against COVID-19 and has been the focus of the world’s health authorities since the beginning of the pandemic. Scientists have dedicated research to the viruses causing the infection as well as to the discovery of the respective vaccines.In the case of Guinea-Bissau, the availability of vaccines was not critical but the reluctance of the population to be vaccinated in view of rumours, phobias and fears about the vaccine and its consequences on the body, especially if you consider the gender aspect, in which it has been mentioned that the vaccination against COVID-19 causes infertility in women of childbearing age and/or other fake news that report death after 2 years of having been vaccinated. Routine vaccination activities were guaranteed with the gradual establishment of vaccination centres in the Autonomous Sector of Bissau (SAB), which evolved from 3 to 14 centres/posts with the active participation of military health technicians after the signing of a partnership agreement.Another relevant aspect to note in the vaccination process against COVID-19 was the digitalisation of the process and the issuing of the vaccination certificate. Despite all these constraints, one year later (april 2021) after the start of vaccination activities the country has reached 50% coverage of the target population, i.e. the population aged 18 years or older, fully vaccinated and 76% of the same population with at least one dose. It is envisaged that vaccination will soon be extended to the adolescent population between 12 and 17 years of age in light of the revision of the National Vaccination Plan (1) and funding opportunities from partners such as the World Bank with the introduction of new vaccines such as MODERNA in the vaccination programme against COVID19. It should be recalled that to date the following vaccines have been used: Astrazeneca, Jansen and Sinopharma. |
id |
RCAP_89a30417189e3054a9fe00f4d1ef31b6 |
---|---|
oai_identifier_str |
oai:ojs.anaisihmt.com:article/428 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Vaccination against SARS-CoV-2 in Guinea-BissauVaccination contre le SRAS-CoV-2 en Guinée-BissauVacinação contra o SARS-CoV-2 na Guiné-BissauVaccination is defined as one of the safest ways to protect against COVID-19 and has been the focus of the world’s health authorities since the beginning of the pandemic. Scientists have dedicated research to the viruses causing the infection as well as to the discovery of the respective vaccines.In the case of Guinea-Bissau, the availability of vaccines was not critical but the reluctance of the population to be vaccinated in view of rumours, phobias and fears about the vaccine and its consequences on the body, especially if you consider the gender aspect, in which it has been mentioned that the vaccination against COVID-19 causes infertility in women of childbearing age and/or other fake news that report death after 2 years of having been vaccinated. Routine vaccination activities were guaranteed with the gradual establishment of vaccination centres in the Autonomous Sector of Bissau (SAB), which evolved from 3 to 14 centres/posts with the active participation of military health technicians after the signing of a partnership agreement.Another relevant aspect to note in the vaccination process against COVID-19 was the digitalisation of the process and the issuing of the vaccination certificate. Despite all these constraints, one year later (april 2021) after the start of vaccination activities the country has reached 50% coverage of the target population, i.e. the population aged 18 years or older, fully vaccinated and 76% of the same population with at least one dose. It is envisaged that vaccination will soon be extended to the adolescent population between 12 and 17 years of age in light of the revision of the National Vaccination Plan (1) and funding opportunities from partners such as the World Bank with the introduction of new vaccines such as MODERNA in the vaccination programme against COVID19. It should be recalled that to date the following vaccines have been used: Astrazeneca, Jansen and Sinopharma.La vaccination est définie comme l’un des moyens les plus sûrs de se protéger contre le COVID19 et fait l’objet de l’attention des autorités sanitaires mondiales depuis le début de la pandémie. Les scientifiques ont consacré des recherches aux virus à l’origine de l’infection ainsi qu’à la découverte des vaccins correspondants.Dans le cas de la Guinée-Bissau, ce n’est pas la disponibilité des vaccins qui a été déterminante, mais la réticence de la population à se faire vacciner en raison des rumeurs, des phobies et des craintes concernant le vaccin et ses conséquences sur le corps, surtout si l’on considère l’aspect genre, à propos duquel il a été mentionné que la vaccination contre le COVID-19 provoque l’infertilité chez les femmes en âge de procréer et/ou autres fausses nouvelles qui font état de décès après 2 ans de vaccination. Les activités de vaccination de routine ont été garanties avec la mise en place progressive de centres de vaccination dans le secteur autonome de Bissau (SAB), qui est passé de 3 à 14 centres/postes avec la participation active de techniciens de santé militaires après la signature d’un accord de partenariat. Un autre aspect pertinent à noter dans le processus de vaccination contre le COVID19 est la numérisation du processus et de l’émission du certificat de vaccination.Malgré toutes ces contraintes, un an plus tard (avril 2021) après le début des activités de vaccination, le pays a atteint une couverture de 50% de la population cible, c’est-à-dire la population âgée de 18 ans ou plus, complètement vaccinée, et 76% de cette même population avec au moins une dose. Il est envisagé d’étendre prochainement la vaccination à la population adolescente entre 12 et 17 ans à la lumière de la révision du Plan National de Vaccination (1) et des opportunités de financement de partenaires tels que la Banque Mondiale avec l’introduction de nouveaux vaccins tels que le MODERNA dans le programme de vaccination contre le COVID19. Il convient de rappeler qu’à ce jour, les vaccins suivants ont été utilisés: Astrazeneca, Jansen et Sinopharma.A vacinação é definida como uma das formas mais segura de proteção contra a COVID-19 e tem merecido desde o início da pandemia a atenção das autoridades sanitárias do mundo. Os cientistas têm dedicado a investigação aos vírus causadores da infeção assim como à descoberta das respetivas vacinas.No caso da Guiné-Bissau a disponibilidade das vacinas não foi crítica mas sim a relutância das populações em se fazer vacinar tendo em conta os rumores, as fobias e receios sobre a vacina e as suas consequências no organismo, sobretudo, se se considerar o aspeto do género e a referência a que a vacinação contra a COVID-19 causa infertilidade nas mulheres em idade fértil e/ou outras fake news que relatam morte após 2 anos de se ter vacinado. As atividades de vacinação de rotina foram garantidas com a criação gradual dos centros de vacinação no Sector Autónomo de Bissau (SAB) que evoluiu de 3 a 14 centros/postos com a participação ativa dos técnicos da saúde militar após assinatura de um acordo de parceria.Um outro aspeto relevante a registar no processo de vacinação contra a COVID-19 foi a digitalização do processo e a emis- são do certificado de vacinação. Não obstante todos estes constrangimentos o país atingiu após um ano (abril de 2021) do início das atividades de vacinação a cobertura de 50% da população alvo, isto é, população de idade igual ou maior os 18 anos completamente vacinada e 76% da mesma população com pelo menos uma dose. Preconiza-se a proximamente estender a vacinação à população adolescen- te dos 12 aos 17 anos de idade à luz da revisão do Plano Nacional de Vacinação (1) e das oportunidades de financiamento dos parceiros como o Banco Mundial com a introdução de novas vacinas como a MODERNA no programa de vacinação contra a COVID-19. Recorde-se que até a data tem-se utilizado as vacinas: Astrazeneca, Jansen e Sinopharma.Universidade Nova de Lisboa2022-10-22info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25761/anaisihmt.428oai:ojs.anaisihmt.com:article/428Anais do Instituto de Higiene e Medicina Tropical; Vol 21 (2022): Estratégias de vacinação em contexto pandémico; 42-47Anais do Instituto de Higiene e Medicina Tropical; v. 21 (2022): Estratégias de vacinação em contexto pandémico; 42-472184-23100303-7762reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://anaisihmt.com/index.php/ihmt/article/view/428https://doi.org/10.25761/anaisihmt.428http://anaisihmt.com/index.php/ihmt/article/view/428/353http://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessCardoso, PlácidoMané, CadijaAraújo Mendonça, GizeloCó, Asson2022-10-26T05:45:20Zoai:ojs.anaisihmt.com:article/428Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:14:03.051271Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Vaccination against SARS-CoV-2 in Guinea-Bissau Vaccination contre le SRAS-CoV-2 en Guinée-Bissau Vacinação contra o SARS-CoV-2 na Guiné-Bissau |
title |
Vaccination against SARS-CoV-2 in Guinea-Bissau |
spellingShingle |
Vaccination against SARS-CoV-2 in Guinea-Bissau Cardoso, Plácido |
title_short |
Vaccination against SARS-CoV-2 in Guinea-Bissau |
title_full |
Vaccination against SARS-CoV-2 in Guinea-Bissau |
title_fullStr |
Vaccination against SARS-CoV-2 in Guinea-Bissau |
title_full_unstemmed |
Vaccination against SARS-CoV-2 in Guinea-Bissau |
title_sort |
Vaccination against SARS-CoV-2 in Guinea-Bissau |
author |
Cardoso, Plácido |
author_facet |
Cardoso, Plácido Mané, Cadija Araújo Mendonça, Gizelo Có, Asson |
author_role |
author |
author2 |
Mané, Cadija Araújo Mendonça, Gizelo Có, Asson |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Cardoso, Plácido Mané, Cadija Araújo Mendonça, Gizelo Có, Asson |
description |
Vaccination is defined as one of the safest ways to protect against COVID-19 and has been the focus of the world’s health authorities since the beginning of the pandemic. Scientists have dedicated research to the viruses causing the infection as well as to the discovery of the respective vaccines.In the case of Guinea-Bissau, the availability of vaccines was not critical but the reluctance of the population to be vaccinated in view of rumours, phobias and fears about the vaccine and its consequences on the body, especially if you consider the gender aspect, in which it has been mentioned that the vaccination against COVID-19 causes infertility in women of childbearing age and/or other fake news that report death after 2 years of having been vaccinated. Routine vaccination activities were guaranteed with the gradual establishment of vaccination centres in the Autonomous Sector of Bissau (SAB), which evolved from 3 to 14 centres/posts with the active participation of military health technicians after the signing of a partnership agreement.Another relevant aspect to note in the vaccination process against COVID-19 was the digitalisation of the process and the issuing of the vaccination certificate. Despite all these constraints, one year later (april 2021) after the start of vaccination activities the country has reached 50% coverage of the target population, i.e. the population aged 18 years or older, fully vaccinated and 76% of the same population with at least one dose. It is envisaged that vaccination will soon be extended to the adolescent population between 12 and 17 years of age in light of the revision of the National Vaccination Plan (1) and funding opportunities from partners such as the World Bank with the introduction of new vaccines such as MODERNA in the vaccination programme against COVID19. It should be recalled that to date the following vaccines have been used: Astrazeneca, Jansen and Sinopharma. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-10-22 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25761/anaisihmt.428 oai:ojs.anaisihmt.com:article/428 |
url |
https://doi.org/10.25761/anaisihmt.428 |
identifier_str_mv |
oai:ojs.anaisihmt.com:article/428 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://anaisihmt.com/index.php/ihmt/article/view/428 https://doi.org/10.25761/anaisihmt.428 http://anaisihmt.com/index.php/ihmt/article/view/428/353 |
dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Nova de Lisboa |
publisher.none.fl_str_mv |
Universidade Nova de Lisboa |
dc.source.none.fl_str_mv |
Anais do Instituto de Higiene e Medicina Tropical; Vol 21 (2022): Estratégias de vacinação em contexto pandémico; 42-47 Anais do Instituto de Higiene e Medicina Tropical; v. 21 (2022): Estratégias de vacinação em contexto pandémico; 42-47 2184-2310 0303-7762 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130593832730624 |